Pricing Log in Create free account
Saturday 17 October 2026 Export EMBC’s income statement to Excel — free account

Embecta Corp.

EMBC Healthcare Medical Instruments & Supplies

Embecta Corp.’s revenue for fiscal 2025 (year ended September 2025) was $1.1 billion, down 3.80% from fiscal 2024. In the quarter to June 2026, revenue fell 8.05%, EPS fell 53.9%, free cash flow fell 49.6% and total debt was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.

6.27 0.18 −2.79%
Market cap
$365.5M
P/E
4.2×
Fwd P/E
3.8×
Dividend yield
5.10%
F-score
7/9
Altman Z
1.84
Beneish M
−3.11
Dividend safety
56/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.56
Total sells 0.04
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — 4 — —
Sell — — — — — — — — — — 1 —
Insider Ownership 11.10%

Capital & Financial Ratios $m

Market Cap 365.46
Revenue 1,018.70
Net Income 87.50
Free Cash Flow 174.70
Net Debt 1,264.30
Current Ratio 1.68 (at or above 1.5: strong)
Debt/Equity (2.42) (negative: negative equity)
P/E ratio 4.21
Fwd P/E 3.76
P/S ratio 0.36
P/B ratio 0.00
Past 5Y EPS Growth (26.40%) (below 0%: weak)
This Y EPS Growth (37.76%) (below 0%: weak)
Next Y EPS Growth (3.96%) (below 0%: weak)
Next Y revenue growth (5.22%) (below 0%: weak)
Next 5Y EPS Growth (12.88%) (below 0%: weak)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.6×, against a ten-year median of 1.9×; over the ten years it ranged from 1.3× in 2026 to 2.8× in 2022.
P/E against its own 10 years 22.39%
10-year low 10-year high
P/S against its own 10 years 9.93%
10-year low 10-year high
EV/Sales against its own 10 years 11.32%
10-year low 10-year high
EV/FCF against its own 10 years 39.10%
10-year low 10-year high

Dividends

Payout Ratio 0.22
Annual Dividend Rate 0.32
Annual Dividend Yield 5.10%
total individual payouts
2028 Powerpack
2027 Powerpack
2026 0.25
0.15
0.01
0.01
2025 0.60
0.15
0.15
0.15
0.15
2024 0.75
0.15
0.15
0.15
0.15
0.15
2023 0.60
0.15
0.15
0.15
0.15
2022 0.30
0.15
0.15
2021 Powerpack
2020 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 327 274 229 218
Receivables 17 193 146 182
Inventory 152 172 179 214
Other 142 54 3 —
749 761 631 705
2023 2024 2025 Q'26
Payables 54 91 74 91
ST’ Debt 10 10 10 139
Other 73 43 16 —
354 374 262 420

Compound Annual Growth %

10y 5y 3y
Sales — (1.50%) (1.47%)
Cash Flow — (15.92%) (22.52%)
Earnings — (25.47%) (24.72%)
Book Value — 0.00% 0.00%

Revenue $m

Dec Mar Jun Sep Year
’26 261 222 272 — —
’25 262 259 296 264 1,080
’24 277 287 273 286 1,123
’23 276 277 286 282 1,121
’22 — 275 291 275 1,130
’21 289 — — — 289
’21 — 284 295 301 1,165
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Dec Mar Jun Sep Year
’26 17 31 42 — —
’25 (5) 32 81 84 192
’24 (13) 24 (2) 27 36
’23 60 (13) (9) 30 68
’22 — 183 33 58 412
’21 139 — — — 139
’21 — 120 130 86 456
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Dec Mar Jun Sep Year
’26 27 31 41 — —
’25 (7) 32 81 77 182
’24 (16) 21 (12) 27 20
’23 56 (19) (16) 20 41
’22 — 177 28 49 388
’21 135 — — — 135
’21 — 113 122 72 417
Fiscal quarters ending in the months shown.

EPS $

Dec Mar Jun Sep Year
’26 0.74 (0.07) 0.36 — —
’25 0.00 0.40 0.78 0.45 1.62
’24 0.35 0.50 0.25 0.25 1.34
’23 0.61 0.24 0.26 0.10 1.22
’22 1.73 1.38 1.07 (0.30) 3.89
’21 — 1.87 1.81 3.60 7.28
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

3.2
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to September

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — — — 23.62 12.72 9.93 9.20

Analyst estimates 2026–2028

Powerpack
High — — — — — — 49.00 33.88 21.48 21.23
People
People Employees — — — — — — 1,900 2,200 2,100 1,850
Revenue/emp, $m — — — 0.00 0.00 0.00 0.59 0.51 0.53 0.58
Income, $m
Income, $m Revenue — — — 1,109 285 289 1,130 1,121 1,123 1,080
Gross margin, % — — — 70.87 67.05 70.48 68.61 66.91 65.46 62.64
EBT — — — 500 125 117 257 106 44 136
EBT margin, % — — — 45.09 43.85 40.30 22.72 9.43 3.94 12.62
Net income — 0 — 432 105 99 224 70 78 95
Depreciation — — — 36 9 8 35 39 49 60
Per share, $
Per share, $ Revenue — — — 0.00 0.00 0.00 19.81 19.58 19.47 18.53
Earnings — — — — 7.50 7.28 3.92 1.23 1.36 1.64
Cash flow — — — 0.00 0.00 0.00 7.23 1.18 0.62 3.29
Capex — — — — 0.00 0.00 (0.42) (0.46) (0.27) (0.16)
Free cash flow — — — 0.00 0.00 0.00 6.81 0.72 0.35 3.13
Book value — — — — 0.00 0.00 (15.63) (14.35) (12.80) (11.16)
Shares, m — — — — 57 57 57 57 58 58
Valuation, ×
Valuation, × P/E — — — 5.22 5.22 5.22 7.40 11.94 10.44 8.66
P/S — — — 2.29 2.29 2.29 1.45 0.75 0.72 0.76
P/B — — — 4.87 4.87 4.87 0.00 0.00 0.00 0.00
EV/Sales — — — 2.29 2.29 2.29 2.61 1.92 1.91 1.87
EV/FCF — — — 6.07 6.07 6.07 7.61 52.17 107.74 11.08
Cash, $m
Cash, $m Operating cash flow — — — 505 121 139 412 68 36 192
Capex — — — (69) (11) (4) (24) (26) (16) (9)
Free cash flow — — — 505 110 135 388 41 20 182
Balance, $m
Balance, $m Working capital — — — — 98 99 364 396 387 370
Total debt — — — — 5 4 1,640 1,635 1,605 1,427
Net debt — — — — 5 4 1,309 1,308 1,331 1,198
Shareholders’ equity — — — — — 551 (891) (822) (738) (651)
Returns, %
Returns, % ROA — — — 0.00 0.00 12.93 24.49 6.12 6.26 8.03
ROIC — — — — 0.00 13.24 46.30 28.44 17.59 27.63
ROE — — — 0.00 0.00 17.26 (131.18) (8.22) (10.04) (13.74)
Negative figures in brackets.

All 10 years →

Fiscal years to Sep 2025 · latest quarter Jun 2026

Charts ten years each

Embecta Corp. vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
AVR Anteris Technologies Global Corp. $619.8M — (loss-making) — +63.27% (above 0%: growing) n/m −6.84% (below 0%: shrinking) 76.91% (3,072.05%) Compare
ANGO AngioDynamics, Inc. $487.0M — (loss-making) — (loss-making) +6.87% (above 0%: growing) n/m +5.62% (above 0%: growing) 59.37% (9.02%) Compare
NNNN Anbio Biotechnology $474.8M — — — — — — — Compare
EMBC Embecta Corp. $365.5M 4.2× 3.8× −8.05% (below 0%: shrinking) −53.85% (below 0%: shrinking) −49.63% (below 0%: shrinking) 56.42% 17.92%
ZJYL Jin Medical International Ltd. $340.9M — — — — −8,074.17% (below 0%: shrinking) 34.44% 0.00% Compare
SMTI Sanara MedTech Inc. $322.4M — (loss-making) 125× +9.04% (above 0%: growing) n/m +131.28% (above 0%: growing) 92.96% 6.33% Compare
OSUR OraSure Technologies, Inc. $262.8M — (loss-making) — (loss-making) −1.93% (below 0%: shrinking) n/m −1.40% (below 0%: shrinking) 43.46% 17.76% Compare
UTMD Utah Medical Products, Inc. $237.8M 22.7× 28.7× −14.31% (below 0%: shrinking) −10.64% (below 0%: shrinking) −55.74% (below 0%: shrinking) 55.79% 31.06% Compare
PDEX Pro-Dex, Inc. $194.1M 13.8× 23.5× +16.65% (above 0%: growing) +143.24% (above 0%: growing) −78.95% (below 0%: shrinking) 34.75% 17.29% Compare
Median of peers $331.7M — 28.7× +7.96% — −6.84% 55.79% 6.33%

All 55 Medical Instruments & Supplies stocks →

Embecta Corp. (EMBC) key facts

  • Concern: Embecta Corp.’s revenue for fiscal 2025 (year ended September 2025) was $1.1 billion, down 3.80% from fiscal 2024.
  • Strength: Net income was $95.4 million, or $1.64 per share (basic), a net margin of 8.83%.
  • Embecta Corp. (EMBC) is a Medical Instruments & Supplies company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, EMBC traded at $6.27, a market capitalization of $365.5 million.
  • At that price the stock trades at 4.2× trailing-twelve-month earnings and 0.4× sales; its P/E is higher than 22% of its own readings over the past ten years.
  • Embecta Corp. pays an annual dividend of $0.32 per share, a yield of 5.10%, with a payout ratio of 21.6%.
  • Return on equity was −13.7% and debt-to-equity -2.42.
  • Its Piotroski F-score is 7 out of 9 and its Altman Z-score is 1.84 (grey zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Embecta Corp. (EMBC) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/EMBC · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com